INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 44h ago
HOUSE PTR4h ago
SEC 13F4h ago
ROBINHOOD CHAIN4h ago
Public company

GILDGILEAD SCIENCES, INC.

CIK 0000882095

EDGAR filingsOpen in network
Disclosed transactions60
Buys / sells3 / 13
Max Insider Score28
Connections24with evidence

GILD · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
7
MJ
Mercier JohannaChief Comm & Corp Aff Officer
GILDGILEAD SCIENCES, INC.
Open-market sale · 10b5-1 plan
SELL$469K
3,000 sh
Oct 15, 2026Oct 16, 2026
traded Oct 15, 2026
+1dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2836 · Biological Products, (No Diagnostic Substances) · Nov 4, 2026
  • ← Connected organizationevidence
    GILEAD SCIENCES INC HEALTHCARE POLICY PACFEC Form 1 connected organization: GILEAD SCIENCES, INC. (curated map) · Nov 4, 2026
  • ← Insider ofevidence
    Berger DietmarChief Medical Officer · Sep 11, 2026
  • ← Lobbied forevidence
    FARRAGUT PARTNERS LLPLDA Q1 2026 first quarter · Health issues, Medicare/Medicaid · Aug 26, 2026
17
BE
Burkhart ErinSVP, Controllership
GILDGILEAD SCIENCES, INC.
Option exercise
M
—
2,223 sh
Sep 22, 2026
Sep 23, 2026
traded Sep 22, 2026
+1d
SEC FORM 4

Evidence

24
BE
Burkhart ErinSVP, Controllership
GILDGILEAD SCIENCES, INC.
Tax withholding
F$117K
768 sh
Sep 22, 2026Sep 23, 2026
traded Sep 22, 2026
+1dSEC FORM 4

Evidence

9
BE
Burkhart ErinSVP, Controllership
GILDGILEAD SCIENCES, INC.
Option exercise
M—
2,223 sh
Sep 22, 2026Sep 23, 2026
traded Sep 22, 2026
+1dSEC FORM 4

Evidence

9
OP
O'Day Daniel PatrickDirector, Chairman & CEO
GILDGILEAD SCIENCES, INC.
Option exercise
M—
8,780 sh
Sep 10, 2026Sep 11, 2026
traded Sep 10, 2026
+1dSEC FORM 4

Evidence

11
OP
O'Day Daniel PatrickDirector, Chairman & CEO
GILDGILEAD SCIENCES, INC.
Tax withholding
F$613K
4,230 sh
Sep 10, 2026Sep 11, 2026
traded Sep 10, 2026
+1dSEC FORM 4

Evidence

5
OP
O'Day Daniel PatrickDirector, Chairman & CEO
GILDGILEAD SCIENCES, INC.
Option exercise
M—
8,780 sh
Sep 10, 2026Sep 11, 2026
traded Sep 10, 2026
+1dSEC FORM 4

Evidence

9
BD
Berger DietmarChief Medical Officer
GILDGILEAD SCIENCES, INC.
Option exercise
M—
533 sh
Sep 10, 2026Sep 11, 2026
traded Sep 10, 2026
+1dSEC FORM 4

Evidence

9
BD
Berger DietmarChief Medical Officer
GILDGILEAD SCIENCES, INC.
Tax withholding
F$38K
263 sh
Sep 10, 2026Sep 11, 2026
traded Sep 10, 2026
+1dSEC FORM 4

Evidence

9
BD
Berger DietmarChief Medical Officer
GILDGILEAD SCIENCES, INC.
Option exercise
M—
533 sh
Sep 10, 2026Sep 11, 2026
traded Sep 10, 2026
+1dSEC FORM 4

Evidence

9
MJ
Mercier JohannaChief Comm & Corp Aff Officer
GILDGILEAD SCIENCES, INC.
Option exercise
M—
2,797 sh
Sep 10, 2026Sep 11, 2026
traded Sep 10, 2026
+1dSEC FORM 4

Evidence

8
MJ
Mercier JohannaChief Comm & Corp Aff Officer
GILDGILEAD SCIENCES, INC.
Tax withholding
F$195K
1,347 sh
Sep 10, 2026Sep 11, 2026
traded Sep 10, 2026
+1dSEC FORM 4

Evidence

5
MJ
Mercier JohannaChief Comm & Corp Aff Officer
GILDGILEAD SCIENCES, INC.
Option exercise
M—
2,797 sh
Sep 10, 2026Sep 11, 2026
traded Sep 10, 2026
+1dSEC FORM 4

Evidence

9
CM
Cain Wettan Keeley MEVP Gen Counsel, Legal & Comp
GILDGILEAD SCIENCES, INC.
Option exercise
M—
590 sh
Sep 10, 2026Sep 11, 2026
traded Sep 10, 2026
+1dSEC FORM 4

Evidence

13
CM
Cain Wettan Keeley MEVP Gen Counsel, Legal & Comp
GILDGILEAD SCIENCES, INC.
Option exercise
M—
590 sh
Sep 10, 2026Sep 11, 2026
traded Sep 10, 2026
+1dSEC FORM 4

Evidence

9
CM
Cain Wettan Keeley MEVP Gen Counsel, Legal & Comp
GILDGILEAD SCIENCES, INC.
Tax withholding
F$41K
285 sh
Sep 10, 2026Sep 11, 2026
traded Sep 10, 2026
+1dSEC FORM 4

Evidence

1
BJ
Bluestone JeffreyDirector
GILDGILEAD SCIENCES, INC.
Open-market sale · 10b5-1 plan
SELL$49K
335 sh
Aug 20, 2026Aug 21, 2026
traded Aug 20, 2026
+1dSEC FORM 4

Evidence

2
BJ
Bluestone JeffreyDirector
GILDGILEAD SCIENCES, INC.
Option exercise · 10b5-1 plan
M$79K
1,165 sh
Aug 20, 2026Aug 21, 2026
traded Aug 20, 2026
+1dSEC FORM 4

Evidence

8
BJ
Bluestone JeffreyDirector
GILDGILEAD SCIENCES, INC.
Open-market sale · 10b5-1 plan
SELL$167K
1,165 sh
Aug 20, 2026Aug 21, 2026
traded Aug 20, 2026
+1dSEC FORM 4

Evidence

2
BJ
Bluestone JeffreyDirector
GILDGILEAD SCIENCES, INC.
Option exercise · 10b5-1 plan
M$122K
1,816 sh
Aug 20, 2026Aug 21, 2026
traded Aug 20, 2026
+1dSEC FORM 4

Evidence

11
BJ
Bluestone JeffreyDirector
GILDGILEAD SCIENCES, INC.
Open-market sale · 10b5-1 plan
SELL$263K
1,816 sh
Aug 20, 2026Aug 21, 2026
traded Aug 20, 2026
+1dSEC FORM 4

Evidence

2
BJ
Bluestone JeffreyDirector
GILDGILEAD SCIENCES, INC.
Option exercise · 10b5-1 plan
M$112K
1,658 sh
Aug 20, 2026Aug 21, 2026
traded Aug 20, 2026
+1dSEC FORM 4

Evidence

8
BJ
Bluestone JeffreyDirector
GILDGILEAD SCIENCES, INC.
Open-market sale · 10b5-1 plan
SELL$242K
1,658 sh
Aug 20, 2026Aug 21, 2026
traded Aug 20, 2026
+1dSEC FORM 4

Evidence

0
BJ
Bluestone JeffreyDirector
GILDGILEAD SCIENCES, INC.
Option exercise · 10b5-1 plan
M$1,754
26 sh
Aug 20, 2026Aug 21, 2026
traded Aug 20, 2026
+1dSEC FORM 4

Evidence

1
BJ
Bluestone JeffreyDirector
GILDGILEAD SCIENCES, INC.
Open-market sale · 10b5-1 plan
SELL$3,805
26 sh
Aug 20, 2026Aug 21, 2026
traded Aug 20, 2026
+1dSEC FORM 4

Evidence

0
BJ
Bluestone JeffreyDirector
GILDGILEAD SCIENCES, INC.
Option exercise · 10b5-1 plan
M$21K
335 sh
Aug 20, 2026Aug 21, 2026
traded Aug 20, 2026
+1dSEC FORM 4

Evidence

0
BJ
Bluestone JeffreyDirector
GILDGILEAD SCIENCES, INC.
Option exercise · 10b5-1 plan
M—
4,665 sh
Aug 20, 2026Aug 21, 2026
traded Aug 20, 2026
+1dSEC FORM 4

Evidence

0
BJ
Bluestone JeffreyDirector
GILDGILEAD SCIENCES, INC.
Option exercise · 10b5-1 plan
M—
335 sh
Aug 20, 2026Aug 21, 2026
traded Aug 20, 2026
+1dSEC FORM 4

Evidence

21
CM
Cain Wettan Keeley MEVP Gen Counsel, Legal & Comp
GILDGILEAD SCIENCES, INC.
Option exercise
M—
6,002 sh
Aug 10, 2026Aug 11, 2026
traded Aug 10, 2026
+1dSEC FORM 4

Evidence

21
CM
Cain Wettan Keeley MEVP Gen Counsel, Legal & Comp
GILDGILEAD SCIENCES, INC.
Option exercise
M—
6,002 sh
Aug 10, 2026Aug 11, 2026
traded Aug 10, 2026
+1dSEC FORM 4

Evidence

27
CM
Cain Wettan Keeley MEVP Gen Counsel, Legal & Comp
GILDGILEAD SCIENCES, INC.
Tax withholding
F$387K
2,908 sh
Aug 10, 2026Aug 11, 2026
traded Aug 10, 2026
+1dSEC FORM 4

Evidence

28
Jared MoskowitzDDependent child
GILDGILEAD SCIENCES, INC.
Purchase
BUY$1,001 – $15KMay 6, 2026Jun 19, 2026
traded May 6, 2026
+44dHOUSE PTR

Evidence

28
Jared MoskowitzDSelf
GILDGILEAD SCIENCES, INC.
Purchase
BUY$1,001 – $15KMay 6, 2026Jun 19, 2026
traded May 6, 2026
+44dHOUSE PTR

Evidence

9
CM
Cain Wettan Keeley MEVP Gen Counsel, Legal & Comp
GILDGILEAD SCIENCES, INC.
Option exercise
M—
589 sh
Jun 10, 2026Jun 11, 2026
traded Jun 10, 2026
+1dSEC FORM 4

Evidence

13
CM
Cain Wettan Keeley MEVP Gen Counsel, Legal & Comp
GILDGILEAD SCIENCES, INC.
Option exercise
M—
589 sh
Jun 10, 2026Jun 11, 2026
traded Jun 10, 2026
+1dSEC FORM 4

Evidence

13
CM
Cain Wettan Keeley MEVP Gen Counsel, Legal & Comp
GILDGILEAD SCIENCES, INC.
Tax withholding
F$34K
283 sh
Jun 10, 2026Jun 11, 2026
traded Jun 10, 2026
+1dSEC FORM 4

Evidence

12
OP
O'Day Daniel PatrickDirector, Chairman & CEO
GILDGILEAD SCIENCES, INC.
Open-market sale · 10b5-1 plan
SELL$895K
6,950 sh
Apr 28, 2026Apr 29, 2026
traded Apr 28, 2026
+1dSEC FORM 4

Evidence

12
OP
O'Day Daniel PatrickDirector, Chairman & CEO
GILDGILEAD SCIENCES, INC.
Open-market sale · 10b5-1 plan
SELL$397K
3,050 sh
Apr 28, 2026Apr 29, 2026
traded Apr 28, 2026
+1dSEC FORM 4

Evidence

12
MJ
Mercier JohannaChief Comm & Corp Aff Officer
GILDGILEAD SCIENCES, INC.
Open-market sale · 10b5-1 plan
SELL$423K
3,000 sh
Apr 15, 2026Apr 16, 2026
traded Apr 15, 2026
+1dSEC FORM 4

Evidence

16
CM
Cain Wettan Keeley MEVP Gen Counsel, Legal & Comp
GILDGILEAD SCIENCES, INC.
Tax withholding
F$90K
606 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC FORM 4

Evidence

13
CM
Cain Wettan Keeley MEVP Gen Counsel, Legal & Comp
GILDGILEAD SCIENCES, INC.
Option exercise
M—
1,246 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC FORM 4

Evidence

17
CM
Cain Wettan Keeley MEVP Gen Counsel, Legal & Comp
GILDGILEAD SCIENCES, INC.
Grant or award
A—
5,050 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC FORM 4

Evidence

9
CM
Cain Wettan Keeley MEVP Gen Counsel, Legal & Comp
GILDGILEAD SCIENCES, INC.
Grant or award
A—
18.9K sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC FORM 4

Evidence

17
BE
Burkhart ErinSVP, Controllership
GILDGILEAD SCIENCES, INC.
Grant or award
A—
2,355 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC FORM 4

Evidence

17
CM
Cain Wettan Keeley MEVP Gen Counsel, Legal & Comp
GILDGILEAD SCIENCES, INC.
Option exercise
M—
1,246 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC FORM 4

Evidence

9
BE
Burkhart ErinSVP, Controllership
GILDGILEAD SCIENCES, INC.
Grant or award
A—
5,455 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC FORM 4

Evidence

13
CM
Cain Wettan Keeley MEVP Gen Counsel, Legal & Comp
GILDGILEAD SCIENCES, INC.
Grant or award
A—
470 sh
Feb 27, 2026Mar 2, 2026
traded Feb 27, 2026
+3dSEC FORM 4

Evidence

24
Josh GottheimerDJoint
GILDGILEAD SCIENCES, INC.
Purchase
BUY$1,001 – $15KJan 27, 2026Feb 26, 2026
traded Jan 27, 2026
+30dHOUSE PTR

Evidence

27
OP
O'Day Daniel PatrickDirector, Chairman & CEO
GILDGILEAD SCIENCES, INC.
Open-market sale · 10b5-1 plan
SELL$15.61M
115.6K sh
Jan 23, 2026Jan 26, 2026
traded Jan 23, 2026
+3dSEC FORM 4

Evidence

12
OP
O'Day Daniel PatrickDirector, Chairman & CEO
GILDGILEAD SCIENCES, INC.
Option exercise · 10b5-1 plan
M$7.63M
115.6K sh
Jan 23, 2026Jan 26, 2026
traded Jan 23, 2026
+3dSEC FORM 4

Evidence

0
OP
O'Day Daniel PatrickDirector, Chairman & CEO
GILDGILEAD SCIENCES, INC.
Option exercise · 10b5-1 plan
M—
115.6K sh
Jan 23, 2026Jan 26, 2026
traded Jan 23, 2026
+3dSEC FORM 4

Evidence

0
BJ
Bluestone JeffreyDirector
GILDGILEAD SCIENCES, INC.
Option exercise · 10b5-1 plan
M—
5,000 sh
Jan 20, 2026Jan 21, 2026
traded Jan 20, 2026
+1dSEC FORM 4

Evidence

13
BJ
Bluestone JeffreyDirector
GILDGILEAD SCIENCES, INC.
Option exercise · 10b5-1 plan
M$337K
5,000 sh
Jan 20, 2026Jan 21, 2026
traded Jan 20, 2026
+1dSEC FORM 4

Evidence

25
BJ
Bluestone JeffreyDirector
GILDGILEAD SCIENCES, INC.
Open-market sale · 10b5-1 plan
SELL$618K
5,000 sh
Jan 20, 2026Jan 21, 2026
traded Jan 20, 2026
+1dSEC FORM 4

Evidence

21
MJ
Mercier JohannaChief Commercial Officer
GILDGILEAD SCIENCES, INC.
Open-market sale · 10b5-1 plan
SELL$373K
3,000 sh
Jan 15, 2026Jan 16, 2026
traded Jan 15, 2026
+1dSEC FORM 4

Evidence

14
OP
O'Day Daniel PatrickDirector, Chairman & CEO
GILDGILEAD SCIENCES, INC.
Open-market sale · 10b5-1 plan
SELL$1.25M
10.0K sh
Dec 29, 2025Dec 30, 2025
traded Dec 29, 2025
+1dSEC FORM 4

Evidence

9
MJ
Mercier JohannaChief Commercial Officer
GILDGILEAD SCIENCES, INC.
Option exercise
M—
3,842 sh
Dec 10, 2025Dec 11, 2025
traded Dec 10, 2025
+1dSEC FORM 4

Evidence

12
MJ
Mercier JohannaChief Commercial Officer
GILDGILEAD SCIENCES, INC.
Tax withholding
F$220K
1,814 sh
Dec 10, 2025Dec 11, 2025
traded Dec 10, 2025
+1dSEC FORM 4

Evidence

13
MJ
Mercier JohannaChief Commercial Officer
GILDGILEAD SCIENCES, INC.
Option exercise
M—
3,842 sh
Dec 10, 2025Dec 11, 2025
traded Dec 10, 2025
+1dSEC FORM 4

Evidence

21
BJ
Bluestone JeffreyDirector
GILDGILEAD SCIENCES, INC.
Option exercise
M—
5,000 sh
Nov 28, 2025Dec 1, 2025
traded Nov 28, 2025
+3dSEC FORM 4

Evidence

  • ← Lobbied forevidence
    GILEAD SCIENCES, INC.LDA Q2 2026 second quarter · Copyright/patent, Budget/appropriations, Taxation, Trade, Health issues, Medicare/Medicaid · Aug 26, 2026
  • ← Lobbied forevidence
    THE DUBERSTEIN GROUP INC.LDA Q1 2026 first quarter · Health issues · Aug 26, 2026
  • ← Lobbied forevidence
    W STRATEGIES, LLCLDA Q1 2026 first quarter · Medicare/Medicaid · Aug 26, 2026
  • ← Lobbied forevidence
    TIBER CREEK GROUPLDA Q2 2026 second quarter · Health issues, Medicare/Medicaid, Budget/appropriations · Aug 26, 2026
  • ← Lobbied forevidence
    JEFFREY J. KIMBELL & ASSOCIATES, INC.LDA Q2 2026 second quarter · Health issues · Aug 26, 2026
  • ← Lobbied forevidence
    EMPIRE CONSULTING GROUPLDA Q1 2026 first quarter · Health issues · Aug 26, 2026
  • ← Lobbied forevidence
    CAPITOL TAX PARTNERS, LLPLDA Q1 2026 first quarter · Taxation · Aug 26, 2026
  • ← Lobbied forevidence
    TODD STRATEGY GROUPLDA Q1 2026 first quarter · Health issues · Aug 26, 2026
  • ← Lobbied forevidence
    FORBES-TATELDA Q2 2026 second quarter · Health issues · Aug 26, 2026
  • ← Lobbied forevidence
    THE MCMANUS GROUPLDA Q2 2026 second quarter · Medicare/Medicaid, Health issues · Aug 26, 2026
  • ← Lobbied forevidence
    TARPLIN, DOWNS & YOUNG, LLCLDA Q2 2026 second quarter · Budget/appropriations, Health issues, Medicare/Medicaid · Aug 26, 2026
  • ← Lobbied forevidence
    MILLER STRATEGIES, LLCLDA Q2 2026 second quarter · Health issues, Budget/appropriations, Medicare/Medicaid · Aug 26, 2026
  • ← Disclosed trade inevidence
    Jared MoskowitzPurchase disclosed 2026-06-19 · Jun 19, 2026
  • ← Insider ofevidence
    Burkhart ErinSVP, Controllership · Mar 12, 2026
  • ← Insider ofevidence
    Cain Wettan Keeley MEVP Gen Counsel, Legal & Comp · Mar 2, 2026
  • ← Disclosed trade inevidence
    Josh GottheimerPurchase disclosed 2026-02-26 · Feb 26, 2026
  • ← Insider ofevidence
    O'Day Daniel PatrickDirector, Chairman & CEO · Dec 30, 2025
  • ← Insider ofevidence
    Mercier JohannaChief Commercial Officer · Dec 11, 2025
  • ← Insider ofevidence
    Bluestone JeffreyDirector · Dec 1, 2025
  • ← Insider ofevidence
    Telman Deborah HEVP, Corporate Affairs & GC · Nov 13, 2025

    • Lobbying

    $6.65M reported · de-duplicated
    2026 Q2 $2.52M via firms2026 Q1 $4.13M via firms
    • TODD STRATEGY GROUP$80K2026 Q2 · posted Aug 26, 2026 · Health issues
    • FORBES-TATE$90K2026 Q2 · posted Aug 26, 2026 · Health issues
    • TARPLIN, DOWNS & YOUNG, LLC$80K2026 Q2 · posted Aug 26, 2026 · Budget/appropriations, Health issues, Medicare/Medicaid
    • MILLER STRATEGIES, LLC$150K2026 Q1 · posted Aug 26, 2026 · Health issues, Budget/appropriations, Medicare/Medicaid
    • TODD STRATEGY GROUP$80K2026 Q1 · posted Aug 26, 2026 · Health issues
    • TARPLIN, DOWNS & YOUNG, LLC$80K2026 Q1 · posted Aug 26, 2026 · Budget/appropriations, Health issues, Medicare/Medicaid
    • GILEAD SCIENCES, INC.$3.19M2026 Q1 · posted Aug 26, 2026 · Trade, Health issues, Medicare/Medicaid, Copyright/patent, Budget/appropriations, Taxation
    • THE DUBERSTEIN GROUP INC.$90K2026 Q2 · posted Aug 26, 2026 · Health issues
    • THE MCMANUS GROUP$60K2026 Q1 · posted Aug 26, 2026 · Medicare/Medicaid, Health issues
    • FORBES-TATE$90K2026 Q1 · posted Aug 26, 2026 · Health issues
    • THE MCMANUS GROUP$60K2026 Q2 · posted Aug 26, 2026 · Medicare/Medicaid, Health issues
    • FARRAGUT PARTNERS LLP$80K2026 Q2 · posted Aug 26, 2026 · Health issues, Medicare/Medicaid

    Connected PAC contributions

    FEC · direct to members
    • Lisa Blunt RochesterD$10KGILEAD SCIENCES INC HEALTHCARE POLICY PAC
    • Kevin MullinD$10KGILEAD SCIENCES INC HEALTHCARE POLICY PAC
    • Brett GuthrieR$10KGILEAD SCIENCES INC HEALTHCARE POLICY PAC
    • Bradley Scott SchneiderD$10KGILEAD SCIENCES INC HEALTHCARE POLICY PAC
    • Deborah K. RossD$10KGILEAD SCIENCES INC HEALTHCARE POLICY PAC
  • Richard HudsonR$10KGILEAD SCIENCES INC HEALTHCARE POLICY PAC
  • Mark R. WarnerD$10KGILEAD SCIENCES INC HEALTHCARE POLICY PAC
  • Troy A. CarterD$10KGILEAD SCIENCES INC HEALTHCARE POLICY PAC
  • Tom ColeR$7,500GILEAD SCIENCES INC HEALTHCARE POLICY PAC
  • Jake AuchinclossD$7,500GILEAD SCIENCES INC HEALTHCARE POLICY PAC
  • H. Morgan GriffithR$7,500GILEAD SCIENCES INC HEALTHCARE POLICY PAC
  • Nanette Diaz BarragánD$7,500GILEAD SCIENCES INC HEALTHCARE POLICY PAC